Company & Sponsor Intelligence

Rhodes Pharmaceuticals, L.P.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials5

Recruiting0

Completed4

Countries1

Therapeutic footprint

adhd

Indexed studies

NCT02470234Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
adhd · United StatesPHASE4

NCT01269463Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
adhd · United StatesPHASE3

NCT02225639PRC-063 in an ADULT Workplace Environment
adhd · United StatesPHASE3

NCT02677519A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
adhd · United StatesPHASE4

NCT01239030Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
adhd · United StatesPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →